Channel Therapeutics Corporation (PTHS)

Last Closing Price: 16.18 (2025-07-03)

Company Description

Channel Therapeutics Corporation is a clinical-stage biotechnology company focused on developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain. The Company's initial clinical focus is to selectively target the sodium ion-channel known as NaV1.7 for the treatment of various types of chronic pain, acute and chronic eye pain and post-surgical nerve blocks. Channel Therapeutics Corporation, formerly known as Chromocell Therapeutics Corporation, is based in FREEHOLD, N.J.

Financials, Fundamental Metrics & Ratios
Revenue (Most Recent Fiscal Year) --
Net Income (Most Recent Fiscal Year) $-7.95M
PE Ratio (Current Year Earnings Estimate) --
PE Ratio (Trailing 12 Months) --
PEG Ratio (Long Term Growth Estimate) --
Price to Sales Ratio (Trailing 12 Months) --
Price to Book Ratio (Most Recent Quarterly Book Value per Share) --
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) --
Pre-Tax Margin (Trailing 12 Months) --
Net Margin (Trailing 12 Months) --
Return on Equity (Trailing 12 Months) --
Return on Assets (Trailing 12 Months) -419.25%
Current Ratio (Most Recent Fiscal Quarter) 0.18
Quick Ratio (Most Recent Fiscal Quarter) 0.18
Debt to Common Equity (Most Recent Fiscal Quarter) --
Inventory Turnover (Trailing 12 Months) --
Book Value per Share (Most Recent Fiscal Quarter) $-4.50
Earnings per Share (Most Recent Fiscal Quarter) --
Earnings per Share (Most Recent Fiscal Year) --
Diluted Earnings per Share (Trailing 12 Months) $-12.40
Stock
Exchange NYSEMKT
Sector Healthcare
Industry Biotechnology
Common Shares Outstanding 0.65M
Free Float 0.54M
Market Capitalization $10.50M
Average Volume (Last 20 Days) 0.02M
Beta (Past 60 Months) 3.63
Percentage Held By Insiders (Latest Annual Proxy Report) 16.40%
Percentage Held By Institutions (Latest 13F Reports) 77.96%
Annual Dividend (Based on Last Quarter) $0.00
Dividend Yield (Based on Last Quarter) 0.00%